Rafael Chiong
Internal Medicine · Miami, FLNPI 1487751012
Payments from drug & device makers
Across 191 payments — averaging $6954.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$699K
- GSK$204K
- Mitsubishi Tanabe Pharma Development America, Inc.$155K
- Cipla USA Inc.$149K
- Endo Pharmaceuticals Inc.$45K
- Sanofi US Services Inc.$28K
- plus $48K from 5 others
What the payments were for
- Food & beverage$117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 30 | $698,584 |
| GSK | 44 | $204,446 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 3 | $154,632 |
| Cipla USA Inc. | 23 | $149,209 |
| Endo Pharmaceuticals Inc. | 11 | $45,422 |
| Sanofi US Services Inc. | 7 | $28,480 |
| Amgen | 1 | $26,144 |
| Merck | 67 | $21,373 |
| AbbVie | 3 | $58 |
| Johnson & Johnson | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
How this compares
$1,328,374 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 340 | $193,077 |
| TradjentaLinagliptin | 275 | $137,002 |
| XareltoRivaroxaban | 153 | $82,488 |
| EntrestoSacubitril/Valsartan | 76 | $50,433 |
| FarxigaDapagliflozin Propanediol | 83 | $46,605 |
| MyrbetriqMirabegron | 70 | $30,839 |
| BrilintaTicagrelor | 67 | $28,728 |
| Tadalafil | 148 | $20,914 |
| JardianceEmpagliflozin | 35 | $20,365 |
| VascepaIcosapent Ethyl | 61 | $20,246 |
| LinzessLinaclotide | 39 | $20,207 |
| TrulicityDulaglutide | 21 | $19,659 |
| MultaqDronedarone Hcl | 22 | $16,779 |
| JanuviaSitagliptin Phosphate | 28 | $15,739 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 159 | $14,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $15 | $82,488153 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $30,83970 claims |
| AbbVieLinzess, Synthroid | $58 | $26,168174 claims |
| MerckJanuvia, Janumet | $21,373 | $23,38542 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $204,446 | $18,55936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Mark KutnerMiami$35.7M
- Mercedes Ponce de LeonMiami$6.8M
- Alejandro de la CruzMiami$6.2M
- Roberto SotolongoMiami$5.8M
- Enrique PelayoMiami$5.4M
- Renato DominguezMiami$5.2M
- Ramses VegaMiami$4.4M
- Dunia Llapur HernandezMiami$4.3M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.